Company intelligence / Profile preview

Takeda

Osaka City, Osaka Prefecture, Japan

Ownership: Public · TAK
Employees: ~49000
Development stage: Commercial

Overview

Takeda has a robust late-stage pipeline with six key assets in Phase 3 or registration stages targeting CNS disorders, autoimmune diseases, hematologic malignancies, and rare genetic conditions. Its lead product Entyvio faces biosimilar competition by the early next decade. The new pipeline could collectively generate $10–20B in peak sales if approved. Recent clinical results include positive data from pivotal trials in narcolepsy and polycythemia vera.[6]

Therapeutic areas: GastroenterologyOncologyImmunologyDermatologyHematologyNeurology
Modalities: Small molecules[10]Antibody-drug conjugates (ADCs)[10]Complex biologics[10]Gamma delta T cell therapies[10]Peptides[6]
Industry: Pharma

Drug pipeline

469 assets

sodium chloride 0.9%

Approved

468 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Takeda.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Takeda.

Explore the full profile